Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system

Table 1 Patient characteristics and disease parameters

	All	Anti-TNF alone	Anti-TNF + DMARDs	DMARDs alone
Age (years)	21 (15–36)	23 (15–29)	27 (18–32)	28 (22–36)
Gender (male/female)	12/44	3/15	6/15	3/14
Disease duration	2 (0.17–10)	0.67 (0.17–3)	2 (0.75–6)	7.5 (3.5–10)
HLA-B27-positive	91.1 % (51/56)	88.9 % (16/18)	90.5 % (19/21)	94.1 % (16/17)
Baseline
SPARCC	32.45 ± 18.71	27.76 ± 18.38	39.53 ± 19.21	28.67 ± 15.51
ASDAS	2.84 ± 1.26	2.56 ± 1.24	3.58 ± 1.05	2.21 ± 1.03
ESR^a	27.10 ± 32.39	27.94 ± 33.24	38.49 ± 38.50	12.14 ± 8.43
CRP^a	17.50 ± 23.07	16.29 ± 23.05	26.29 ± 28.02	7.919 ± 5.60

^aNot normally distributed, compared by paired rank test
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor